Universiteit Leiden

nl en


PD fellow "Mast cells as effectors in hemorrhage and acute cardiovascular diseases"

Omvang (fte)
Geplaatst op
19 december 2023
30 januari 2024 Vacature gesloten

PD fellow “Mast cells as effectors in hemorrhage and acute cardiovascular diseases”

Vacancy number: 14423

The Faculty of Science Leiden and the Division of BioTherapeutics at the Leiden Academic Centre for Drug Research are looking for a post-doctoral fellow for the project ‘Mast cells as effectors in hemorrhage and acute cardiovascular diseases’.

Project description
Acute cardiovascular syndromes (ACS) are the main cause of death in Western society and are caused by atherosclerosis in the arterial wall. Intraplaque hemorrhage is a key characteristic of an unstable atherosclerotic plaque at risk for rupture, leading to ACS such as stroke. Therapeutic approaches to prevent the incidence of intraplaque hemorrhage is a powerful strategy to limit the incidence of ACS and reduce overall disease burden. Intraplaque hemorrhage is caused by leakage of intraplaque microvessels. We hypothesize that the mast cell, a prominent pro-inflammatory immune cell type, induces microvascular instability in advanced atherosclerosis and is causally involved in the incidence of intraplaque hemorrhage. In this program, we aim to a) elucidate how mast cells in the atherosclerotic plaque contribute to microvessel instability and intraplaque hemorrhage and b) develop therapeutic strategies inhibiting mast cell induced vascular leakage to prevent intraplaque hemorrhage and subsequent ACS.

Key responsibilities
The applicant will:

  • Provide mechanistic insights in mast cell-endothelial cell interactions in advanced atherosclerosis.
  • Design and test new therapeutic strategies to prevent intraplaque hemorrhage in advanced atherosclerosis.
  • Use a combination of murine and human atherosclerotic material
  • Closely collaborate with our international consortium partners from the ERA4Health program “MASTer”.

Selection criteria
We are looking for an enthusiastic, bright, well-motivated, and ambitious scientist:

  • With a recent PhD degree in the field of Biopharmaceutical Sciences, Biomedical Sciences, Biology, or equivalent and a strong interest in cardiovascular research.
  • With proficiency in English, both verbally and in writing.
  • Who is an independent and creative team player with good communicative skills.
  • Experience with in vivo studies (FELASA laboratory animal science certificate), flow cytometry, single cell technology (working in R, Python) and microscopical techniques is an advantage.

We offer
We offer a full-time position for three years. Salary ranges from € 3.226,- to € 5.090,- gross per month for Postdoc (fulltime, pay scale 10, depending on experience), in accordance with the Collective Labour Agreement for Dutch Universities.
Leiden University offers an attractive benefits package with additional holiday (8%) and end-of-year bonuses (8.3 %), training and career development. Our individual choices model gives you some freedom to assemble your own set of terms and conditions. For international spouses we have set up a dual career programme. Candidates from outside the Netherlands may be eligible for a substantial tax break. For more information, see the website.

Diversity and inclusion
Fostering an inclusive community is a central element of the values and vision of Leiden University. Leiden University is committed to becoming an inclusive community which enables all students and staff to feel valued and respected and to develop their full potential. Diversity in experiences and perspectives enriches our teaching and strengthens our research. High quality teaching and research is inclusive. LACDR is a highly diverse institute, in culture, background, and gender. We stand for excellence in a caring Institute. We wish to reflect society in all aspects, as we believe that this improves the dynamics in our organization. Therefore, we support and understand the need for a work/life/family balance and consequent varying working hours and places. We believe that doing good science is fun, and goes hand in hand with a friendly culture.

LACDR, Division of BioTherapeutics
The division of BioTherapeutics is part of the Leiden Academic Centre for Drug Research (LACDR). Our institute is a centre of excellence for multidisciplinary research on drug discovery and development. Leiden University consistently ranks within the top-20 world-wide within the subject-based QS Ranking in Pharmacology and Pharmacy. At LACDR, we develop innovative scientific concepts in fundamental and translational research underlying the discovery and optimization of drugs, and personalised medicines. We aim to optimise the route to novel drugs that are both efficacious and safe, and therefore our research focuses on drug discovery and safety, biotherapeutics, and systems biomedicine and pharmacology. State-of-the-art expertise and infrastructures ensure that we are strategically positioned in (inter)national collaborations, thus further strengthening the development of novel concepts and their application in a clinical and industry environment. More information about LACDR you find on the website, see https://www.universiteitleiden.nl/en/science/drug-research.

The division of BioTherapeutics operates at the forefront of research in the field of therapeutic modulation of cardiovascular disease. The research aims to identify new immune targets in atherosclerosis and to develop innovative biopharmaceutical concepts to intervene in cardiovascular disease. The use of specific gene-knockout technology, biologics such as vaccines, therapeutic proteins and cellular therapy, provides a unique approach for the development of new therapies for the treatment or prevention of atherosclerosis. For more information, see https://www.universiteitleiden.nl/en/science/drug-research/biotherapeutics.

The Faculty of Science at Leiden University is a world-class faculty where staff and students work together in a dynamic international environment. It is a faculty where personal and academic development are top priorities. Our people are committed to expand fundamental knowledge by curiosity and to look beyond the borders of their own discipline; their aim is to benefit science, and to make a contribution to addressing the major societal challenges of the future.

Leiden University is one of Europe’s leading international research universities. Thanks to its committed and inspired employees, the university enjoys a leading role in academic research and education. Leiden also scores very well every year in prominent rankings. This means that, to maintain our position, the bar is set very high. Regardless of the work you do at our university, you are always encouraged to broaden your horizons, develop your talents and reach your full potential. Will you become our newest colleague?

Do you have questions about this position? For more information concerning the scientific content, please contact Dr. Bot (e-mail: i.bot@lacdr.leidenuniv.nl). If you have any questions about the recruitment process, please contact Mrs. Cathy van der Ploeg (e-mail: c.c.m.van.der.ploeg@lacdr.leidenuniv.nl, telephone: +31 71 527 5134).

You can find more information about the faculty of Science at https://www.universiteitleiden.nl/en/science/about-faculty-of-science. For more information about working at Leiden university please visit https://www.universiteitleiden.nl/en/working-at.

In order to be eligible, make sure you send your complete application before the deadline of the call. Please respond via the blue button on this page enclosing the following documents (in pdf format), in English:

Please ensure that you upload the following additional document quoting the vacancy number:

  • Motivation letter;
  • An updated curriculum vitae, including a list of publications and a link to your PhD thesis;
  • Written letters of recommendation by at least two former supervisors.
  • The closing date is January 30, 2024.

Acquisition following this advertisement is not appreciated.

Deze website maakt gebruik van cookies.  Meer informatie.